Übersetzung für "analytical specificity " (Englisch → Französisch) :

use analytics for commercial purpose | work with analytics for commercial purposes | use analytics for commercial purposes | use commercial analytics

instruments of analytical chemistry | methods of analytical chemistry | analytical chemistry | analytical chemistry studies

operate analytically | run analytically | proceed analytically | work analytically

analytic entry | analytical description | analytical entry

analytical electron microscopy [ AEM | analytical electron transmission microscopy | transmission analytical electron microscopy ]

analytical procedures | analysis | analytical review | analytics

virus-specific detection program [ virus-specific detection programme | specific detection program | specific detection programme | virus-specific scanning software | specific scanning software ]

analytic [ analytical ]

We have no analytical method by which to arrive at a specific cost; we could only look at comparators and speculate on what the cost could be in a Canadian context over the long term.

4. Welcomes the Commission’s Single Market integration report 2014 (COM(2013)0785)) and strongly supports the Commission’s efforts to integrate the Single Market further in the considerations of the European Semester; appreciates the fact that the report on the state of the Single Market in 2014 contains a number of elements specifically relating to actions taken by individual Member States; considers nevertheless that the report still lacks any qualitative assessment of the effectiveness of measures taken, progress made and policy results actually achieved; calls for the development of an analytical ...[+++] tool to measure Single Market integration within the framework of the Single Market pillar of the European Semester in relation to the country-specific recommendations; believes that this analytical tool could further complement the Internal Market Scoreboard;

4. Welcomes the Commission’s Single Market integration report 2014 (COM(2013)0785)) and strongly supports the Commission’s efforts to integrate the Single Market further in the considerations of the European Semester; appreciates the fact that the report on the state of the Single Market in 2014 contains a number of elements specifically relating to actions taken by individual Member States; considers nevertheless that the report still lacks any qualitative assessment of the effectiveness of measures taken, progress made and policy results actually achieved; calls for the development of an analytical ...[+++] tool to measure Single Market integration within the framework of the Single Market pillar of the European Semester in relation to the country-specific recommendations; believes that this analytical tool could further complement the Internal Market Scoreboard;

Question No. 53 Ms. Kirsty Duncan: With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and treatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) ho ...[+++]w is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with bo ...